Targeted inhibition of myeloid-derived suppressor cells by doxorubicin
to enhance antigen-specific cytotoxic T lymphocytes killing
neuroblastoma cells in vitro
Abstract
Background High agglomeration of myeloid-derived suppressor cell (MDSC)
in neuroblastoma (NB) resulted in immune tolerance and impeded
therapeutic effects. Doxorubicin (DOX) is currently found the most
specific drug to selectively remove MDSC. However, whether these
mechanisms can relieve the inhibitory role of MDSC in NB immunotherapy
is still remain unclear. Procedure In this study, the inhibitory role of
MDSC for NB Ag-specific cytotoxic T lymphocyte (CTL) were investigated
in vitro. CTLs, NB cells, MDSCs and DOX were mixed and cultivated in
different collocation pattern, the levels of cluster of differentiation
3ζ chain (CD3ζ) and L-selectin in CTL in different groups were detected.
Thereafter, the killing rate of neuroblastoma cells, secretion of
interleukin-2 and interferon-γ were detected and compared. Results The
proliferation and killing effect of CTLs on neuroblastoma cells were all
inhibited by MDSC through downregulating CD3ζ (P = 0.002; P = 0.001) and
L-selectin (P = 0.006; P < 0.001) by reai-time PCR test and by
Western-blot analysis respectively. However, this inhibitory role can be
effectively reversed by doxorubicin. The significant difference existed
in the killing rate between the groups (P < 0.001) except
between CTL+SK-N-SH group and CTL+SK-N-SH+DOX group (P >
0.05). There were significant differences in the levels of IL-2 (P
< 0.001) and IFN-γ (P < 0.001) among the groups.
Conclusions This study provided the novel method to enhance
immunotherapeutic effects for neuroblastoma by using doxorubicin to
targeted inhibition of MDSCs.